Our Company
We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with GI and liver diseases.
There are more than 3 million people in the United States with IBD.
There are more than 3 million people in the United States with IBD.
Programs
Organovo has acquired the FXR Program. For more information, please go to www.organovo.com